Immunohistochemistry: This antibody stained human brain stroke (including control cortex and stroke core areas) tissue. The primary antibody was incubated at 2.5 mg/ml overnight at 4°C. This was followed by a fluorophore conjugated secondary antibody. Optimal concentrations and conditions may vary. Information and photo are courtesy of the Tissue Profiling group, SciLifeLab Stockholm. Neutralization: To yield one-half maximal inhibition [ND] of the biological activity of hIL-11 (1.50 ng/ml), a concentration of 0.02-0.05 ug/ml of this antibody is required. ELISA: To detect hIL-11 by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5-2 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with Biotinylated Anti-Human IL-11 (LS-C104365
) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of recombinant hIL-11. Western Blot: To detect hIL-11 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 ug/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-11 is 1.5-3 ng/lane, under either reducing or non-reducing conditions.